T-cell exhaustion in glioblastoma.
作者信息
Woroniecka Karolina, Fecci Peter E
机构信息
Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA; Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA; Department of Pathology, Duke University Medical Center, Durham, NC, USA.
出版信息
Oncotarget. 2018 Oct 19;9(82):35287-35288. doi: 10.18632/oncotarget.26228.
Abstract
摘要
相似文献
1
T-cell exhaustion in glioblastoma.
Oncotarget. 2018 Oct 19;9(82):35287-35288. doi: 10.18632/oncotarget.26228.
2
T Cell Exhaustion in Glioblastoma: Intricacies of Immune Checkpoints.
Trends Immunol. 2017 Feb;38(2):104-115. doi: 10.1016/j.it.2016.11.005. Epub 2016 Dec 7.
3
T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma.
Clin Cancer Res. 2018 Sep 1;24(17):4175-4186. doi: 10.1158/1078-0432.CCR-17-1846. Epub 2018 Feb 7.
4
Colorectal Cancer-Associated Immune Exhaustion Involves T and B Lymphocytes and Conventional NK Cells and Correlates With a Shorter Overall Survival.
Front Immunol. 2021 Dec 16;12:778329. doi: 10.3389/fimmu.2021.778329. eCollection 2021.
5
Combination checkpoint therapy with anti-PD-1 and anti-BTLA results in a synergistic therapeutic effect against murine glioblastoma.
Oncoimmunology. 2021 Aug 29;10(1):1956142. doi: 10.1080/2162402X.2021.1956142. eCollection 2021.
6
Expression and Prognostic Value of the Immune Checkpoints Galectin-9 and PD-L1 in Glioblastomas.
J Neuropathol Exp Neurol. 2021 Jun 4;80(6):541-551. doi: 10.1093/jnen/nlab041.
7
Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition.
Neuro Oncol. 2019 Jun 10;21(6):730-741. doi: 10.1093/neuonc/noz015.
8
Cancer immunotherapy by targeting immune checkpoints: mechanism of T cell dysfunction in cancer immunity and new therapeutic targets.
J Biomed Sci. 2017 May 25;24(1):35. doi: 10.1186/s12929-017-0341-0.
9
Immunotherapy for recurrent glioblastoma: practical insights and challenging prospects.
Cell Death Dis. 2021 Mar 19;12(4):299. doi: 10.1038/s41419-021-03568-0.
10
Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer.
Genome Med. 2020 Feb 28;12(1):22. doi: 10.1186/s13073-020-00722-9.
引用本文的文献
1
Design of a novel multiepitope vaccine against glioblastoma by in silico approaches.
Sci Rep. 2025 Jul 5;15(1):24046. doi: 10.1038/s41598-025-03672-7.
2
Recent developments in peptide vaccines against Glioblastoma, a review and update.
Mol Brain. 2025 Jun 13;18(1):50. doi: 10.1186/s13041-025-01221-x.
3
Immunotherapy for High-Grade Gliomas.
Cancers (Basel). 2025 May 31;17(11):1849. doi: 10.3390/cancers17111849.
4
Exploring the immune environment of glioblastoma through single-cell RNA sequencing in humanized mouse models.
bioRxiv. 2025 May 22:2025.05.17.654526. doi: 10.1101/2025.05.17.654526.
5
The Basis for Targeting the Tumor Macrophage Compartment in Glioblastoma Immunotherapy.
Cancers (Basel). 2025 May 12;17(10):1631. doi: 10.3390/cancers17101631.
6
Role of T Lymphocytes in Glioma Immune Microenvironment: Two Sides of a Coin.
Biology (Basel). 2024 Oct 21;13(10):846. doi: 10.3390/biology13100846.
7
Pembrolizumab in an HIV-infected patient with glioblastoma.
Immunotherapy. 2024;16(12):803-811. doi: 10.1080/1750743X.2024.2362566. Epub 2024 Jun 18.
8
Non-Tumor Cells within the Tumor Microenvironment-The "Eminence Grise" of the Glioblastoma Pathogenesis and Potential Targets for Therapy.
Cells. 2024 May 9;13(10):808. doi: 10.3390/cells13100808.
9
[Zr]-CD8 ImmunoPET imaging of glioblastoma multiforme response to combination oncolytic viral and checkpoint inhibitor immunotherapy reveals CD8 infiltration differential changes in preclinical models.
Theranostics. 2024 Jan 1;14(3):911-923. doi: 10.7150/thno.89206. eCollection 2024.
10
Limited Effects of Class II Transactivator-Based Immunotherapy in Murine and Human Glioblastoma.
Cancers (Basel). 2023 Dec 30;16(1):193. doi: 10.3390/cancers16010193.
本文引用的文献
1
Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors.
Nat Med. 2018 Sep;24(9):1459-1468. doi: 10.1038/s41591-018-0135-2. Epub 2018 Aug 13.
2
T-cell Dysfunction in Glioblastoma: Applying a New Framework.
Clin Cancer Res. 2018 Aug 15;24(16):3792-3802. doi: 10.1158/1078-0432.CCR-18-0047. Epub 2018 Mar 28.
3
T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma.
Clin Cancer Res. 2018 Sep 1;24(17):4175-4186. doi: 10.1158/1078-0432.CCR-17-1846. Epub 2018 Feb 7.
4
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.
Nat Commun. 2016 Feb 17;7:10501. doi: 10.1038/ncomms10501.
5
Immunotherapy for primary brain tumors: no longer a matter of privilege.
Clin Cancer Res. 2014 Nov 15;20(22):5620-9. doi: 10.1158/1078-0432.CCR-14-0832.
6
An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme.
Neuro Oncol. 2006 Jul;8(3):234-43. doi: 10.1215/15228517-2006-006. Epub 2006 May 24.
7
Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma.
Cancer Res. 2006 Mar 15;66(6):3294-302. doi: 10.1158/0008-5472.CAN-05-3773.
8
Immune defects observed in patients with primary malignant brain tumors.
J Neuroimmunol. 1999 Dec;100(1-2):216-32. doi: 10.1016/s0165-5728(99)00203-9.
9
Cytokinetic basis for the impaired activation of lymphocytes from patients with primary intracranial tumors.
J Immunol. 1984 Mar;132(3):1208-15.
Zotero 插件